Association Governance
Association Board
The ATMP Sweden board unites expertise spanning the full ATMP landscape – from early-stage research, manufacturing, and clinical translation, to regulatory affairs, patient advocacy, and commercial deployment. Members are drawn from academia, hospital-based practice, biotech, and industry, ensuring the board can address both the scientific and strategic challenges of advancing ATMPs in Sweden and beyond.
Elias Uhlin
Chairman
Leads the Pre-GMP Facility at Lund Stem Cell Center, advancing ATMPs from research to clinic. He drives collaboration across academia, healthcare, and industry, and as ATMP Sweden Chair, works to strengthen national coordination and patient access.
Michael Delahaye
Board Member
Senior Director at CCRM Nordic, has 15+ years in cell and gene therapy. He specializes in scalable manufacturing and characterization, and supports collaboration, knowledge sharing, and global integration of Swedish ATMP innovation.
Kerstin Sollerbrant
Board Member
Senior Expert at the Swedish Childhood Cancer Fund and EMA CAT representative, advocates for patient perspectives in ATMP development. She works to accelerate access to innovative therapies for cancer, rare, and genetic diseases.
Alexandra Karström
Board Member
Leads cell and tissue therapy at Uppsala University Hospital, overseeing clinical-grade cell production for burn care. She contributes nationally through expert groups and drives quality, standards, and clinical implementation of ATMPs.
Jenny Nelander
Board Secretary
Lund University researcher focused on translating stem cell therapies to the clinic. She contributed to Sweden’s first ATMP trial in Parkinson’s and brings expertise in preclinical, clinical, and regulatory aspects of ATMP development.
Björn Skölving
Board Member
Has 20+ years in pharma, with a focus on ATMP launches including Sweden’s first CAR-T therapy. He brings expertise in market access, implementation, and cross-border care to expand patient access and enable ATMP adoption.
Lindsay Davies
Board Member
CEO of CellTherEx Consulting and CSO at NextCell Pharma, specializing in translational cell therapy. She bridges academia and industry, contributes internationally, and works to advance innovation and access to ATMPs.
Magdalena Bengtsson Levin
Board Treasurer
Has served in Public and External Affairs, as well as Regional Access in Johnson & Johnson for over a decade, with a principal focus on facilitating patient access to innovative oncology and hematology treatments. Over the past three years, she has played a pivotal role in orchestrating initiatives to enhance awareness of advanced therapies among healthcare payers and policy stakeholders.
Pierfrancesco Pagella
Board Member